Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02513472 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 258
- Enrollment target
NCT02513472 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 258 participants.
The verdict
NCT02513472, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 258 participants
- Enrollment target
Study Summary
This is an open-label, single-arm, multicenter, Phase 1b/2 study of eribulin mesylate in combination with pembrolizumab in participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
Interventions
- DRUG Pembrolizumab
- DRUG Eribulin Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2015-08-28 |
| Est. Completion | 2021-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02513472
The ClinicalTrials.gov registry entry for NCT02513472 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02513472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02513472 about?
NCT02513472 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)". This is an open-label, single-arm, multicenter, Phase 1b/2 study of eribulin mesylate in combination with pembrolizumab in participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metasta...
What is the current status of trial NCT02513472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 258 participants. The study started on 2015-08-28. Estimated completion is 2021-04-06.
What interventions are being tested in trial NCT02513472?
The interventions under investigation include: Pembrolizumab (DRUG), Eribulin Mesylate (DRUG).
Who is sponsoring clinical trial NCT02513472?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.